Abstract P2-12-23: A phase 2 trial combining tiragolumab and atezolizumab with neoadjuvant or first line chemotherapy for triple negative breast cancer (SKYLINE)
François‐Clément Bidard(Inserm), Fatima Mechta-Grigoriou(Inserm), Florence Coussy(Inserm), Nina Jehanno(Physique des Cellules et Cancers), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Toulsie Ramtohul(Université Paris Sciences et Lettres), Diana Bello-Roufai(Hôpital René Huguenin), Agathe Peltier, Irène Buvat(Centre National de la Recherche Scientifique), Julien Fouque, Romain‐David Seban(Institut Curie), Laurence Champion(Institut Curie)
Cited by 0
Related Papers
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
|Journal of Clinical Oncology|2022|676
METhodological RadiomICs Score (METRICS): a quality scoring tool for radiomics research endorsed by EuSoMII
|Insights into Imaging|2024|286
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268